Novartis Femara
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA approves letrozole Jan. 10 for first-line treatment of hormone receptor-positive or hormone receptor-unknown advanced metastatic breast cancer in postmenopausal women. Femara was shown to be superior to tamoxifen in median time to tumor progression and rate of objective tumor response in a Phase III trial, labeling states. The sNDA for the new indication, submitted July 2000, was given priority review status. Femara has been approved for second-line treatment of advanced breast cancer in postmenopausal women since 199
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.